Your browser doesn't support javascript.
loading
Early COVID-19 vaccine effectiveness of XBB.1.5 vaccine against hospitalisation and admission to intensive care, the Netherlands, 9 October to 5 December 2023.
van Werkhoven, C Henri; Valk, Anne-Wil; Smagge, Bente; de Melker, Hester E; Knol, Mirjam J; Hahné, Susan Jm; van den Hof, Susan; de Gier, Brechje.
Affiliation
  • van Werkhoven CH; Center for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
  • Valk AW; Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands.
  • Smagge B; Center for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
  • de Melker HE; Center for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
  • Knol MJ; Center for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
  • Hahné SJ; Center for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
  • van den Hof S; Center for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
  • de Gier B; Center for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
Euro Surveill ; 29(1)2024 01.
Article in En | MEDLINE | ID: mdl-38179623
ABSTRACT
We present early vaccine effectiveness (VE) estimates of the 2023 seasonal COVID-19 XBB.1.5 vaccine against COVID-19 hospitalisation and admission to an intensive care unit (ICU) in previously vaccinated adults ≥ 60 years in the Netherlands. We compared vaccination status of 2,050 hospitalisations including 92 ICU admissions with age group-, sex-, region- and date-specific population vaccination coverage between 9 October and 5 December 2023. VE against hospitalisation was 70.7% (95% CI 66.6-74.3), VE against ICU admission was 73.3% (95% CI 42.2-87.6).
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Vaccines / COVID-19 Limits: Adult / Humans Country/Region as subject: Europa Language: En Journal: Euro Surveill Journal subject: DOENCAS TRANSMISSIVEIS Year: 2024 Document type: Article Affiliation country: Netherlands Country of publication: Sweden

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Vaccines / COVID-19 Limits: Adult / Humans Country/Region as subject: Europa Language: En Journal: Euro Surveill Journal subject: DOENCAS TRANSMISSIVEIS Year: 2024 Document type: Article Affiliation country: Netherlands Country of publication: Sweden